STOCK MARKET BSE NSE

COVID-19: WHO to end anti-malaria drug hydroxycholorquine trial for coronavirus cure

WHO says a review of the interim results showed hcq and lopinavir/ritonavir 'produce little or no reduction in the mortality of hospitalized COVID-19 patients when compared to standard care.'

Published: 05th July 2020 09:36 AM  |   Last Updated: 05th July 2020 09:36 AM   |  A+A-

A chemist displays hydroxychloroquine tablets (Photo | AP)

A chemist displays hydroxychloroquine tablets (Photo | AP)

By Associated Press

BERLIN: The World Health Organization says it is ending a trial into whether anti-malaria drug hydroxychloroquine helps patients hospitalised with COVID-19.

WHO said Saturday it has "accepted the recommendation" from the committee overseeing the trial to discontinue testing of hydroxychloroquine and lopinavir/ritonavir, a drug combination used to treat HIV/AIDS.

The drugs were being compared with standard care for hospitalized patients.

WHO says a review of the interim results showed hydroxychloroquine and lopinavir/ritonavir "produce little or no reduction in the mortality of hospitalized COVID-19 patients when compared to standard of care."

The agency adds that while there was no "solid evidence" of increased mortality for hospitalized patients given the drugs, there were "some associated safety signals in the clinical laboratory findings" of an associated trial.

WHO says the decision won't affect possible trials on patients who aren't hospitalized, or on those receiving the drugs before potential exposure to the coronavirus or shortly afterward.


Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

IPL_2020
flipboard facebook twitter whatsapp